CRH Medical (CRHM) Upgraded by Zacks Investment Research to “Buy”

Zacks Investment Research upgraded shares of CRH Medical (NYSEAMERICAN:CRHM) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning. The firm currently has $2.75 target price on the stock.

According to Zacks, “CRH Medical Corporation offers products and services to physicians for the treatment of gastrointestinal diseases primarily in the United States. The company provides the CRH O’Regan System, a single use, disposable and hemorrhoid banding technology for treating hemorrhoid grades I – IV. It distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians. The company utilizes Web-based platform to connect doctors with patients as well as educating its install base of physicians. It also offers anesthesia services. CRH Medical Corporation is headquartered in Vancouver, Canada. “

How to Become a New Pot Stock Millionaire

Shares of CRH Medical (NYSEAMERICAN:CRHM) opened at $2.60 on Tuesday. The stock has a market capitalization of $229.48, a price-to-earnings ratio of 28.89 and a beta of 1.14. CRH Medical has a 12-month low of $1.46 and a 12-month high of $9.25.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. bought a new position in CRH Medical in the second quarter valued at $150,000. Ramsey Quantitative Systems purchased a new stake in shares of CRH Medical during the fourth quarter worth about $128,000. TD Asset Management Inc. boosted its holdings in shares of CRH Medical by 65.3% during the third quarter. TD Asset Management Inc. now owns 111,054 shares of the company’s stock worth $289,000 after purchasing an additional 43,851 shares during the period. Baird Financial Group Inc. purchased a new stake in shares of CRH Medical during the fourth quarter worth about $301,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of CRH Medical by 69.1% during the third quarter. JPMorgan Chase & Co. now owns 410,100 shares of the company’s stock worth $964,000 after purchasing an additional 167,600 shares during the period.

COPYRIGHT VIOLATION NOTICE: “CRH Medical (CRHM) Upgraded by Zacks Investment Research to “Buy”” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3294890/crh-medical-crhm-upgraded-by-zacks-investment-research-to-buy.html.

CRH Medical Company Profile

CRH Medical Corporation is a Canada-based healthcare products and services company. The Company focused on providing physicians with services and products for the treatment of gastrointestinal diseases. The Company also provides anesthesiology services to gastroenterologists in the United States through its subsidiaries.

Get a free copy of the Zacks research report on CRH Medical (CRHM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for CRH Medical (NYSEAMERICAN:CRHM)

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Champion International Paper  Set to Announce Earnings on Thursday
Champion International Paper Set to Announce Earnings on Thursday
Starbucks  Scheduled to Post Quarterly Earnings on Thursday
Starbucks Scheduled to Post Quarterly Earnings on Thursday
Valley National Bank  Set to Announce Earnings on Thursday
Valley National Bank Set to Announce Earnings on Thursday
Piper Jaffray Comments on SRC Energy’s Q1 2018 Earnings
Piper Jaffray Comments on SRC Energy’s Q1 2018 Earnings
Brokers Issue Forecasts for BioTelemetry Inc’s Q1 2018 Earnings
Brokers Issue Forecasts for BioTelemetry Inc’s Q1 2018 Earnings
Total S.A.  Forecasted to Earn Q1 2018 Earnings of $1.05 Per Share
Total S.A. Forecasted to Earn Q1 2018 Earnings of $1.05 Per Share


© 2006-2018 Ticker Report. Google+.